Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Androgen-Independent Prostatic Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchEnded earlyNCT04116164
What this trial is testing

Safety and Targeting of Anti-hk2 Antibody in mCRPC

Who this might be right for
Castration-Resistant Prostatic CancerMetastatic Disease
SpectronRX 27
Not applicableStudy completedNCT02398526
What this trial is testing

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases

Who this might be right for
Castration-Resistant Prostatic Cancer
Bayer 363
Testing effectiveness (Phase 2)Study completedNCT00459186
What this trial is testing

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Who this might be right for
Metastatic, Androgen Independent Prostate CancerProstate Cancer
Dana-Farber Cancer Institute 19
Testing effectiveness (Phase 2)Study completedNCT00878436
What this trial is testing

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Who this might be right for
Prostate CancerProstatic Neoplasms
NYU Langone Health 52
Testing effectiveness (Phase 2)Study completedNCT00081172
What this trial is testing

Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Ended earlyNCT00096304
What this trial is testing

Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Medical University of South Carolina 36
Testing effectiveness (Phase 2)Study completedNCT00683475
What this trial is testing

IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Who this might be right for
Prostate Cancer
Eli Lilly and Company 138
Early research (Phase 1)Study completedNCT00113984
What this trial is testing

Vaccine and Antibody Treatment of Prostate Cancer

Who this might be right for
Prostatic Neoplasms
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Study completedNCT00134355
What this trial is testing

Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer

Who this might be right for
Prostate Cancer
University of Michigan Rogel Cancer Center 5
Testing effectiveness (Phase 2)Study completedNCT00064610
What this trial is testing

Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Millennium Pharmaceuticals, Inc. 102
Testing effectiveness (Phase 2)Study completedNCT00182741
What this trial is testing

Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
OHSU Knight Cancer Institute 19
Early research (Phase 1)Active Not RecruitingNCT04597411
What this trial is testing

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Endocyte 101
Testing effectiveness (Phase 2)Study completedNCT01540071
What this trial is testing

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostate Cancer
Io Therapeutics 38
Testing effectiveness (Phase 2)Study completedNCT00480090
What this trial is testing

A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer

Who this might be right for
Prostate Cancer
University Health Network, Toronto 10
Early research (Phase 1)Looking for participantsNCT05519449
What this trial is testing

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerCastration Resistant Prostatic Cancer
Janux Therapeutics 272
Testing effectiveness (Phase 2)UnknownNCT02049190
What this trial is testing

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Prostate CancerAndrogen-independent Prostate Cancer+1 more
Arno Therapeutics 75
Not applicableUnknownNCT00133900
What this trial is testing

Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy

Who this might be right for
Hormone Refractory Prostate CancerProstate Cancer
Immunicon 276
Testing effectiveness (Phase 2)Study completedNCT00350051
What this trial is testing

ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer

Who this might be right for
Prostate Cancer
Bayer 53
Testing effectiveness (Phase 2)Study completedNCT00090545
What this trial is testing

A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 46
Testing effectiveness (Phase 2)Study completedNCT00084825
What this trial is testing

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Who this might be right for
Metastatic CancerProstate Cancer
M.D. Anderson Cancer Center 23
Next Page